Rx0000144 |
Helsinn Therapeutics, Inc |
09/30/2021 |
69639010501 |
AKYNZEO Intravenous Solution 235-0.25 MG/20ML |
07/01/2021 |
13.41 |
683.19 |
06/02/2037 |
Single Source Drug |
25000 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
n/a |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000144 |
Helsinn Therapeutics, Inc |
09/30/2021 |
69639010201 |
AKYNZEO Intravenous Solution Reconstituted 235MG/0.25MG PER VIAL |
07/01/2021 |
13.41 |
683.19 |
06/02/2037 |
Single Source Drug |
400 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
n/a |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000144 |
Helsinn Therapeutics, Inc |
09/30/2021 |
69639012001 |
VALCHLOR 0.016% Gel 60gm tube |
07/01/2021 |
318.91 |
4874.69 |
07/08/2029 |
Single Source Drug |
620 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
n/a |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000119 |
Heron Therapeutics, Inc. |
03/31/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial |
01/01/2021 |
8.65 |
392.84 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000119 |
Heron Therapeutics, Inc. |
06/30/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial |
04/01/2021 |
8.84 |
401.68 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000119 |
Heron Therapeutics, Inc. |
09/30/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial; injectable emulsion |
07/01/2021 |
9.04 |
410.72 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000119 |
Heron Therapeutics, Inc. |
12/31/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial; injectable emulsion |
10/01/2021 |
9.24 |
419.96 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143993125 |
Cefotaxime Sodium Injection Solution Reconstituted 1gm |
02/15/2021 |
10.45 |
65.45 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
This product was previously removed from the market due to a discontinuation of the raw material we use from our supplier. Hikma had to reinvest in the product to find a new API supplier and R&D work to qualify and reintroduce the product. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143993325 |
Cefotaxime Sodium Injection Solution Reconstituted 2gm |
02/15/2021 |
23.75 |
148.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
This product was previously removed from the market due to a discontinuation of the raw material we use from our supplier. Hikma had to reinvest in the product to find a new API supplier and R&D work to qualify and reintroduce the product. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143978710 |
Enalaprilat Intravenous Injection 1.25mg/mL, 1mL |
02/15/2021 |
4.35 |
48.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143978610 |
Enalaprilat Intravenous Injection 1.25mg/mL, 2mL |
02/15/2021 |
7.77 |
86.28 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641602110 |
Famotidine Intravenous Solution 200mg/20mL |
02/15/2021 |
7.92 |
87.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641602325 |
Famotidine Intravenous Solution 40mg/4mL |
02/15/2021 |
5.58 |
61.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641604610 |
Lorazepam Injection Solution 2mg/mL |
02/15/2021 |
9.59 |
106.46 |
None |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641604710 |
Lorazepam Injection Solution 4mg/mL, 10mL |
02/15/2021 |
13.04 |
144.77 |
None |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641604525 |
Lorazepam Injection Solution 4mg/mL, 1mL |
02/15/2021 |
6.36 |
70.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641094835 |
Promethazine HCl Injection Solution 25 MG/ML, Qty 25 |
10/01/2021 |
22.64 |
43.64 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641094935 |
Promethazine HCl Injection Solution 50mg/mL, 1mL, Qty 25 |
10/01/2021 |
16.64 |
62.89 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641095525 |
Promethazine Hydrochloride Solution Injection Solution 25 MG/ML, Qty 25 |
10/01/2021 |
22.14 |
43.64 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641095625 |
Promethazine Hydrochloride Solution Injection Solution 50mg/mL, 1mL, Qty 25 |
10/01/2021 |
44.89 |
91.14 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
Rx0000145 |
Horizon Therapeutics USA, Inc. |
03/31/2021 |
75987008010 |
Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial |
02/01/2021 |
1138.06 |
24847.56 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Columns left blank contain non-public information. Acquisition columns left blank because this product was not acquired within the last five years. |